Rohto Pharmaceutical completes JPY 5bn share repurchase

Rohto Pharmaceutical (TSE:4527) announced the completion of its share repurchase program initiated on February 26, 2025. The company acquired 2,174,300 of its own shares through an off-auction transaction (ToSTNeT-3) on the Tokyo Stock Exchange, for a total expenditure of ¥4,999,802,850. This move concludes the repurchase plan authorized by the board, with an initial intention to repurchase up to 2,430,000 shares for a maximum of ¥5 billion between February 27, 2025, and April 30, 2025. The company stated that the share repurchase aims to improve ROE and EPS, and to mitigate the impact of a recent issuance of Zero Coupon Convertible Bonds on the company's stock.